HMGCR and atherosclerosis: As reported, rosuvastatin exerts that effect via competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis, and this effect contributes a lot in attenuating atherosclerosis development (Cortese et al., 2016).